Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming ...
Homology Medicines, Inc. is a genetic medicines...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
We discover and develop medicines to defeat neurodegeneration. The science is brea...
We discover and develop medicines to defeat neu...
Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...
Allenaâs lead product candidate, reloxaliase,...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.